Product Description: Vatalanib dihydrochloride (PTK787 dihydrochloride) is an inhibitor of VEGFR2/KDR with IC50 of 37 nM.
Applications: Cancer-Kinase/protease
Formula: C20H17Cl3N4
Citations: Bioact Mater. 2 January 2022./Br J Pharmacol. 2019 Sep;176(17):3143-3160. /Evid-Based Compl Alt. 2021 Apr 27./JCI Insight. 2024 May 22;9(10):e166402./Kitazato Graduate School of Pharmaceutical Sciences. Kitasato University. 2017./Oncol Rep. 2016 Mar;35(3):1297-308./Oxid Med Cell Longev. 18 Jul 2022./Sci Transl Med. 2018 Jul 18;10(450):eaaq1093./Ulm University. 2023 Mar 21./Drug Metab Pharmacokinet. 2017 Jun;32(3):179-188. /Int J Mol Sci. 2024 Nov 15;25(22):12277./J Microbiol Biotechnol. 2015 Aug;25(8):1227-33. /J Pharm Anal. 2023 Sep 11./Patent. US20170349880A1.
References: [1]Wood JM, et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. 2000, 60(8/[2]Murakami M, et al. Tyrosine kinase inhibitor PTK/ZK enhances the antitumor effects of interferon-α/5-fluorouracil therapy for hepatocellular carcinoma cells. Ann Surg Oncol. 2011, 18(2), 589-596./[3]Wan J, et al. Local recurrence of small cell lung cancer following radiofrequency ablation is induced by HIF-1α expression in the transition zone. Oncol Rep. 2016 Mar;35(3):1297-308.
CAS Number: 212141-51-0
Molecular Weight: 419.73
Compound Purity: 99.68
Research Area: Cancer
Solubility: DMSO : 50 mg/mL (ultrasonic;warming;heat to 80°C)/H2O : 50 mg/mL (ultrasonic)
Target: Apoptosis;VEGFR
English
Deutsch
